Skip to content
    Real-World Studies

    Neoadjuvant vs Adjuvant Chemo-Immunotherapy and Survival in Triple-Negative Breast Cancer

    Komatsu et alCancers

    Neoadjuvant vs Adjuvant Chemo-Immunotherapy and Survival in Triple-Negative Breast Cancer
    In a retrospective National Cancer Database (NCDB) study evaluating 21,757 women with clinical stage II-III triple-negative breast cancer (TNBC) diagnosed between 2017 and 2023 who underwent definitive surgery and received chemo-immunotherapy, neoadjuvant treatment was associated with improved overall survival (OS) compared with adjuvant chemo-immunotherapy. Within the cohort, 21,340 patients received neoadjuvant chemo-immunotherapy while 417 received adjuvant treatment. Factors associated with receiving neoadjuvant therapy included higher clinical T stage, node-positive disease, and diagnosis between 2021 and 2023.
    Overall survival was evaluated via Kaplan-Meier analysis, univariable and multivariable Cox proportional hazards regression, and propensity-score overlap weighting. The 1-, 2-, and 3-year OS rates were 98.8%, 93.2%, and 88.6% for neoadjuvant chemo-immunotherapy compared with 94.3%, 88.9%, and 81.6% for adjuvant chemo-immunotherapy. Neoadjuvant therapy was associated with reduced mortality risk across univariable (HR 0.58, 95% CI 0.46–0.72; p < 0.001), multivariable (HR 0.52, 95% CI 0.42–0.66; p < 0.001), and overlap-weighted models (HR 0.57, 95% CI 0.45–0.73; p < 0.001). Prespecified subgroup analyses consistently favored neoadjuvant treatment across clinical T- and N-stage categories. The authors noted that these hypothesis-generating findings align with clinical practice patterns following KEYNOTE-522, but emphasize cautious interpretation as the NCDB does not capture differences in specific treatment regimens or completion rates that could have contributed to the observed survival differences.

    Key Takeaways

    • Neoadjuvant chemo-immunotherapy was associated with improved overall survival compared to adjuvant therapy in multivariable analysis (HR 0.52, 95% CI 0.42-0.66; p < 0.001) and propensity-score overlap weighting (HR 0.57, 95% CI 0.45-0.73; p < 0.001).
    • Patients receiving neoadjuvant vs adjuvant chemo-immunotherapy achieved higher 1-, 2-, and 3-year overall survival rates: 98.8% vs 94.3%, 93.2% vs 88.9%, and 88.6% vs 81.6%, respectively.